Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10,228 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I and pharmacokinetic study of nab-paclitaxel, nanoparticle albumin-bound paclitaxel, administered weekly to Japanese patients with solid tumors and metastatic breast cancer.
Ando M, Yonemori K, Katsumata N, Shimizu C, Hirata T, Yamamoto H, Hashimoto K, Yunokawa M, Tamura K, Fujiwara Y. Ando M, et al. Among authors: yamamoto h. Cancer Chemother Pharmacol. 2012 Feb;69(2):457-65. doi: 10.1007/s00280-011-1726-5. Epub 2011 Aug 19. Cancer Chemother Pharmacol. 2012. PMID: 21853310 Clinical Trial.
64Cu-DOTA-trastuzumab PET imaging in patients with HER2-positive breast cancer.
Tamura K, Kurihara H, Yonemori K, Tsuda H, Suzuki J, Kono Y, Honda N, Kodaira M, Yamamoto H, Yunokawa M, Shimizu C, Hasegawa K, Kanayama Y, Nozaki S, Kinoshita T, Wada Y, Tazawa S, Takahashi K, Watanabe Y, Fujiwara Y. Tamura K, et al. Among authors: yamamoto h. J Nucl Med. 2013 Nov;54(11):1869-75. doi: 10.2967/jnumed.112.118612. Epub 2013 Sep 12. J Nucl Med. 2013. PMID: 24029656 Free article.
A phase I/II trial of olaparib tablet in combination with eribulin in Japanese patients with advanced or metastatic triple-negative breast cancer previously treated with anthracyclines and taxanes.
Yonemori K, Shimomura A, Yasojima H, Masuda N, Aogi K, Takahashi M, Naito Y, Shimizu S, Nakamura R, Hashimoto J, Yamamoto H, Hirakawa A, Michimae H, Hamada A, Yoshida T, Sukigara T, Tamura K, Fujiwara Y. Yonemori K, et al. Among authors: yamamoto h. Eur J Cancer. 2019 Mar;109:84-91. doi: 10.1016/j.ejca.2018.11.014. Epub 2019 Jan 28. Eur J Cancer. 2019. PMID: 30703739 Clinical Trial.
Second-line chemotherapy in patients with primary unknown cancer.
Ono M, Ando M, Yonemori K, Yamamoto H, Hirata T, Shimizu C, Tamura K, Katsumata N, Fujiwara Y. Ono M, et al. Among authors: yamamoto h. J Cancer Res Clin Oncol. 2011 Aug;137(8):1185-91. doi: 10.1007/s00432-011-0983-3. Epub 2011 May 11. J Cancer Res Clin Oncol. 2011. PMID: 21559815
Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer.
Ono M, Tsuda H, Shimizu C, Yamamoto S, Shibata T, Yamamoto H, Hirata T, Yonemori K, Ando M, Tamura K, Katsumata N, Kinoshita T, Takiguchi Y, Tanzawa H, Fujiwara Y. Ono M, et al. Among authors: yamamoto h, yamamoto s. Breast Cancer Res Treat. 2012 Apr;132(3):793-805. doi: 10.1007/s10549-011-1554-7. Epub 2011 May 12. Breast Cancer Res Treat. 2012. PMID: 21562709
Comparison of dose intensity of vincristine, d-actinomycin, and cyclophosphamide chemotherapy for child and adult rhabdomyosarcoma: a retrospective analysis.
Kojima Y, Hashimoto K, Ando M, Yonemori K, Yamamoto H, Kodaira M, Yunokawa M, Shimizu C, Tamura K, Hosono A, Makimoto A, Fujiwara Y. Kojima Y, et al. Among authors: yamamoto h. Cancer Chemother Pharmacol. 2012 Sep;70(3):391-7. doi: 10.1007/s00280-012-1920-0. Epub 2012 Jul 18. Cancer Chemother Pharmacol. 2012. PMID: 22806306
10,228 results
You have reached the last available page of results. Please see the User Guide for more information.